Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $193.00 at UBS Group
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by equities research analysts at UBS Group from $174.00 to $193.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 43.37% from the company’s […]